XML 63 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Other (Income)/Deductions - Net (Footnotes) (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Oct. 01, 2017
Oct. 02, 2016
Oct. 01, 2017
Oct. 02, 2016
Jun. 30, 2017
Loss Contingencies [Line Items]          
Royalty revenue [1] $ 140 $ 233 $ 331 $ 695  
Gain on sale of investments 66   183    
Gain on sale of property     52    
Intangible asset impairment charges   $ 126   767  
Income from contract resolution 62   62 116  
Payments for merger termination costs       $ 150  
Laboratorio Teuto Brasilero [Member]          
Loss Contingencies [Line Items]          
Equity method investment, ownership percentage   40.00%   40.00% 40.00%
Loss on disposal of equity method investment     30    
Equity method investment, impairment       $ 50  
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]          
Loss Contingencies [Line Items]          
Equity method investment, ownership percentage   49.00%   49.00%  
Equity method investment, impairment       $ 211  
Xtandi [Member]          
Loss Contingencies [Line Items]          
Royalty revenue 73   160    
Distribution Rights [Member]          
Loss Contingencies [Line Items]          
Gain on disposition of intangible assets 71   141 49  
Developed Technology Rights [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charges       331  
Collaborative Arrangement, Co-promotion [Member] | Enbrel [Member]          
Loss Contingencies [Line Items]          
Decrease in royalty revenue 139   $ 414    
Royalty period     36 months    
Pending Litigation [Member] | Celebrex [Member]          
Loss Contingencies [Line Items]          
Litigation settlement expense 94   $ 94    
Pending Litigation [Member] | Celebrex and Bextra [Member]          
Loss Contingencies [Line Items]          
Amount awarded to other party       486  
In Process Research and Development [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charges       265  
Other In Process Research and Development [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charges       74  
Hospira [Member] | Other In Process Research and Development [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charges       45  
InnoPharma [Member] | In Process Research and Development [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charges   $ 97   97  
King [Member] | Other In Process Research and Development [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charges   29   29  
Operating Segments [Member] | EH [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charges   97   738  
Operating Segments [Member] | EH [Member] | Hospira [Member] | Developed Technology Rights [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charges 127   127    
Operating Segments [Member] | IH [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charges   $ 29   $ 29  
Operating Segments [Member] | IH [Member] | ViiV Healthcare Limited [Member]          
Loss Contingencies [Line Items]          
Dividend income 54   211    
Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]          
Loss Contingencies [Line Items]          
Ownership percentage         60.00%
Patent Matter [Member] | Pending Litigation [Member]          
Loss Contingencies [Line Items]          
Litigation settlement expense $ 79   $ 79    
[1] Royalty-related income decreased in the third quarter and first nine months of 2017, primarily due to lower royalty income for Enbrel of $139 million and $414 million, respectively, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of $73 million and $160 million, respectively.